Evidence map›Paper›PMID 38341600›Full record

ArticleDiabetology & metabolic syndrome2024

Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease.

Xing-Jian Zhang, Cong-Cong Liu, Zuo-Lin Li, Lin Ding, Yan Zhou, Dong-Jie Zhang, Yao Zhang, Shu-Ting Hou, Rui-Xia Ma

Open access · goldAbstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Xing-Jian Zhang *Department of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Cong-Cong Liu *Department of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Zuo-Lin Li *Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China. zuolin_li1990@126.com.
Lin DingDepartment of Nephrology, Minda Hospital Affiliated to Hubei Minzu University, Enshi, Hubei, China.
Yan ZhouInstitute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu, China.
Dong-Jie ZhangDepartment of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yao ZhangDepartment of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Shu-Ting HouDepartment of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Rui-Xia MaDepartment of Nephrology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. anita1685@163.com.
Affiliated Hospital of Qingdao University · CNQingdao University · CNMinda Hospital · CNSoutheast University · CNZhongda Hospital Southeast University · CN

Funding

Fundamental Research Funds for the Central Universities 2242023K40046National Natural Science Foundation of China 82000648Natural Science Foundation of Shandong Province ZR2022MH161Outstanding Youth Cultivation Foundation of Southeast University 2021ZDYYYQPY07Qingdao Medical and Health Research Program Project 2021-WJZD189
6 · The paper itself

Abstract

backgroundTubulointerstitial fibrosis plays an important role in the progression of diabetic kidney disease (DKD). Sacubitril/valsartan (Sac/Val) exerts a robust beneficial effect in DKD. However, the potential functional effect of Sac/Val on tubulointerstitial fibrosis in DKD is still largely unclear.

methodsStreptozotocin-induced diabetic mice were given Sac/Val or Val by intragastric administration once a day for 12 weeks. The renal function, the pathological changes of tubule injury and tubulointerstitial fibrosis, as well as mitochondrial morphology of renal tubules in mice, were evaluated. Genome-wide gene expression analysis was performed to identify the potential mechanisms. Meanwhile, human tubular epithelial cells (HK-2) were cultured in high glucose condition containing LBQ657/valsartan (LBQ/Val). Further, mitochondrial functions and Sirt1/PGC1α pathway of tubular epithelial cells were assessed by Western blot, Real-time-PCR, JC-1, MitoSOX or MitoTracker. Finally, the Sirt1 specific inhibitor, EX527, was used to explore the potential effects of Sirt1 signaling in vivo and in vitro.

resultsWe found that Sac/Val significantly ameliorated the decline of renal function and tubulointerstitial fibrosis in DKD mice. The enrichment analysis of gene expression indicated metabolism as an important modulator in DKD mice with Sac/Val administration, in which mitochondrial homeostasis plays a pivotal role. Then, the decreased expression of Tfam and Cox IV;, as well as changes of mitochondrial function and morphology, demonstrated the disruption of mitochondrial homeostasis under DKD conditions. Interestingly, Sac/Val administration was found to restore mitochondrial homeostasis in DKD mice and in vitro model of HK-2 cells. Further, we demonstrated that Sirt1/PGC1α, a crucial pathway in mitochondrial homeostasis, was activated by Sac/Val both in vivo and in vitro. Finally, the beneficial effects of Sac/Val on mitochondrial homeostasis and tubulointerstitial fibrosis was partially abolished in the presence of Sirt1 specific inhibitor.

conclusionsTaken together, we demonstrate that Sac/Val ameliorates tubulointerstitial fibrosis by restoring Sirt1/PGC1α pathway-mediated mitochondrial homeostasis in DKD, providing a theoretical basis for delaying the progression of DKD in clinical practice.

Indexed as

Diabetic kidney diseaseMitochondriaPGC1αSacubitril/valsartanSirt1Tubulointerstitial fibrosis

Identifiers

PMID38341600
PMCPMC10858505
OpenAlexW4391717941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.